Efficacy and Safety of Oral Erlotinib in TRPV3-related Olmsted Syndrome: a Case Series
Published: 12 June 2025| Version 1 | DOI: 10.17632/ppxxcgpz9b.1
Contributors:
Xuewan Zhang, Ruzeng Xue, Huijun Wang, Zeqiao Zhang, Zhimiao LinDescription
Supplementary figures (A-B, C-D). Clinical images of OS patients treated with erlotinib A and B, patient 10, with the TRPV3 p.Gly573Ser mutation, achieved complete remission of hyperkeratosis. C and D, patient 9, with the TRPV3 p.Met672Ile mutation, exhibited only partial remission of skin hyperkeratosis. Supplementary figures (E, F). Adverse effects of 2 patients treated with erlotinib E, Severe acneiform eruption in patient 3 after two weeks of erlotinib treatment. F, Diffuse hair loss in patient 2 after two months of erlotinib treatment. Supplementary figures (G-I). Immunofluorescence staining of phospho-epidermal growth factor receptor (p-EGFR) in normal control, patient 9, and patient 4 before erlotinib treatment.
Files
Categories
Dermatology, Palmar Plantar Keratoderma